Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 61

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 61
---
 with
the SEC. The amendments in this ASU require public business entities to disclose on an annual and interim basis, disaggregated information
about certain income statement expense line items. The new standard is effective for fiscal years beginning after December 15, 2026, with
early adoption permitted. We are currently evaluating the impact that ASU 2024-03 will have on our financial statement disclosures.

ITEM 3. Quantitative and Qualitative Disclosures
about Market Risk

As a smaller reporting company as defined by Rule
12b-2 of the Exchange Act of 1934, as amended and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations
and therefore are not required to provide the information requested by this item.

ITEM 4. Controls and Procedures. Disclosure
Controls and Procedures 

Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, have
evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under
the Exchange Act) as of March 31, 2025. Based on that evaluation, the Company’s Chief Executive Officer and the Company’s
Chief Financial Officer have concluded that as of March 31, 2025, due to the existence of the material weakness in the Company’s
internal control over financial reporting described below, the Company’s disclosure controls and procedures were not effective.

Management is responsible for establishing and
maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the
Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief
Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used
the framework set forth in the report entitled “Internal Control-Integrated Framework (2013)” published by the Committee of
Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based
on that assessment, our management has identified certain material weaknesses in our internal control over financial reporting.

Our management concluded that as of March 31, 2025,
our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas:

(1)we do not employ full time